AstraZeneca’s Ultomiris® (ravulizumab-cwvz) is now approved to treat generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor antibody positive.

• Myasthenia gravis is a rare neuromuscular condition that causes severe weakness and loss of muscle function. Ultomiris is the first drug in its class approved to treat gMG.
• The FDA first approved Ultomiris in The drug is also indicated to treat paroxysmal nocturnal hemoglobinuria or atypical hemolytic uremic syndrome in patients at least one month of age.
• Recommended dosing is based on the patient’s diagnosis and body. To treat gMG, Ultomiris is administered via intravenous infusion once every eight weeks.